Welcome to our dedicated page for Schrodinger news (Ticker: SDGR), a resource for investors and traders seeking the latest updates and insights on Schrodinger stock.
Schrodinger, Inc. (SDGR) combines cutting-edge computational physics with life sciences innovation to transform drug discovery and materials development. This dedicated news hub provides investors and researchers with essential updates about the company's scientific advancements and strategic initiatives.
Access timely information on SDGR's software innovations, collaborative research milestones, and regulatory developments. Our curated collection includes press releases covering clinical trial progress, technology partnerships, and financial performance updates.
Key content categories include quarterly earnings reports, molecular simulation platform enhancements, preclinical program updates, and strategic alliances with pharmaceutical leaders. Bookmark this page for direct access to primary source materials that inform investment decisions and industry analysis.
Copernic Catalysts and Schrödinger (SDGR) announced they have surpassed the final technical milestone for their jointly developed ammonia synthesis catalyst, Neptune. Neptune delivered an ammonia yield >2x that of competing catalysts under real-world reactor conditions and met the collaboration's success criteria.
The release states Neptune could raise industrial plant capacity by up to 47%, add up to $110 million in annual plant-level profit, and cut energy use from the Haber-Bosch process by up to 23%. Copernic is scaling up with toll manufacturers and plans pilot-scale demonstrations in 2026/27, with commercial sales targeted after successful pilots. Copernic and Schrödinger have also begun joint work on a selective ethylene oxide catalyst.
Schrödinger (Nasdaq: SDGR) will report its third quarter 2025 financial results on Wednesday, November 5, 2025 after the market close. The company will host a conference call and live webcast at 4:30 p.m. ET. The live webcast is available in the company’s Investors section and will be archived for approximately 90 days following the event.
Schrödinger (Nasdaq: SDGR) reported that on October 13, 2025 it granted restricted stock units (RSUs) covering 14,888 shares to 10 newly hired employees as inducement awards under the company’s 2021 Inducement Equity Incentive Plan.
The grants were approved by the compensation committee under authority delegated by the board and were made in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs vest over four years: 25% vests after 12 months of continuous service, then three equal annual installments of 25% each on subsequent anniversaries. Awards are subject to the award agreements and plan terms.
Schrödinger (Nasdaq: SDGR) has granted restricted stock units (RSUs) to four newly hired employees on September 14, 2025. The inducement grants total 1,666 shares of common stock and were issued under the company's 2021 Inducement Equity Incentive Plan.
The RSUs feature a four-year vesting schedule, with 25% vesting after 12 months of continuous service, followed by equal yearly installments of 25% over the subsequent three years. These grants were approved by the compensation committee and comply with Nasdaq Listing Rule 5635(c)(4).
Schrödinger (Nasdaq: SDGR) announced its upcoming participation in the Morgan Stanley 23rd Annual Global Healthcare Conference. The company's management will engage in a fireside chat scheduled for Monday, September 8, 2025, at 11:30 a.m. E.T. Investors can access the live webcast through the "Investors" section of Schrödinger's website, where it will remain available for approximately 90 days after the event.
Schrödinger (Nasdaq: SDGR) announced the granting of inducement equity awards to two new employees on August 15, 2025. The company awarded a total of 1,875 restricted stock units (RSUs) under its 2021 Inducement Equity Incentive Plan.
The RSUs feature a four-year vesting schedule, with 25% vesting after the first year of continuous service and the remaining 75% vesting in equal yearly installments over the following three years. These grants were approved by the compensation committee and comply with Nasdaq Listing Rule 5635(c)(4).
Schrödinger (Nasdaq: SDGR) announced the discontinuation of its SGR-2921 clinical development program, a CDC7 inhibitor being evaluated in a Phase 1 dose-escalation study for acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes.
The decision comes after two treatment-related deaths in AML patients during the Phase 1 study, despite early evidence of monotherapy activity. The company determined that pursuing development as a combination therapy would be challenging, despite preclinical data showing promising anti-leukemic responses in patient-derived AML models.
Schrödinger (Nasdaq: SDGR) reported Q2 2025 financial results with total revenue of $54.8 million, up 16% year-over-year. Software revenue increased 15% to $40.5 million, while drug discovery revenue reached $14.2 million.
The company presented encouraging Phase 1 data for its MALT1 inhibitor SGR-1505 in B-cell malignancies and received FDA Fast Track Designation for Waldenström macroglobulinemia treatment. Initial clinical data for two other programs, SGR-3515 and SGR-2921, is expected in Q4 2025.
Schrödinger maintained its 2025 software revenue growth guidance of 10-15% and implemented cost-reduction measures, including a 7% workforce reduction expected to save approximately $30 million annually.
Schrödinger (Nasdaq: SDGR) has scheduled its second quarter 2025 financial results announcement for Wednesday, August 6, 2025, after market close. The company will hold a conference call and webcast at 4:30 p.m. ET to discuss the results. Investors can access the live webcast through the "Investors" section of Schrödinger's website, where it will remain available for approximately 90 days.
Schrödinger (Nasdaq: SDGR) announced the granting of restricted stock units (RSUs) to three new employees as part of their employment compensation packages. The grants, totaling 3,488 shares of common stock, were issued on July 14, 2025, under the company's 2021 Inducement Equity Incentive Plan.
The RSUs feature a four-year vesting schedule, with 25% vesting after the first year of continuous service and the remaining 75% vesting in equal yearly installments over the following three years. These grants were approved by the compensation committee and comply with Nasdaq Listing Rule 5635(c)(4).
FAQ
What is the current stock price of Schrodinger (SDGR)?
What is the market cap of Schrodinger (SDGR)?
